Results 21 to 30 of about 755,616 (163)

MOESM7 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

open access: yes, 2019
Additional file 7: Figure S7. Gating strategy for B-cell subsets in mice. Representative gating strategy used for mice experiments for the identification of GC B-cells (CD19+CD95+IgDlow), IgA GC B-cells (CD19+CD95+IgDlowIgA+), plasma cells (CD19lowCD138+) and IgA+ plasma cells (CD19lowCD138+IgA+).
Heukels, Peter   +13 more
openaire   +1 more source

Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton’s Tyrosine Kinase

open access: yes, 2021
Although Bruton’s tyrosine kinase (BTK) has been recognized as a validated drug target for the treatment of B-cell malignances, the emergence of clinical resistance to the first-generation covalent BTK inhibitors is becoming a serious concern.
Masaaki Sawa (5801243)   +6 more
core   +1 more source

MOESM10 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

open access: yes, 2019
Additional file 10: Table S1. Overview of antibodies used for experiments.
Heukels, Peter   +13 more
openaire   +1 more source

MOESM11 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

open access: yes, 2019
Additional file 11: Methods S1. Procedures of mouse experiments.
Heukels, Peter   +13 more
openaire   +1 more source

Switching immune signals on and off

open access: yeseLife, 2015
Bruton's tyrosine kinase, an enzyme that is important for B cell function, can be activated in a number of ways.
Nam Chu, Philip A Cole
doaj   +1 more source

MOESM6 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

open access: yes, 2019
Additional file 6: Figure S6. Autoreactive IgG and IgM does not correlate with disease progression. Fluorescence intensity for plasma autoreactive IgG (A) and IgM (B) does not correlate with decline in forced vital capacity (FVC) over 1-year period in IPF patients. Correlation coefficients were calculated using Spearmanâ s rank method.
Heukels, Peter   +13 more
openaire   +1 more source

MOESM9 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

open access: yes, 2019
Additional file 9:. Graphic summary of B-cell subset alterations and autoreactive IgA induction in IPF patients. Immature B cells leave the bone marrow as transitional B-cells for further differentiation. Decrease in circulating transitional B-cells together with their increase in IPF lungs suggest homing towards pulmonary tertiary lymphoid organs (TLO)
Heukels, Peter   +13 more
openaire   +1 more source

MOESM1 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

open access: yes, 2019
Additional file 1: Figure S1. No changes of proportions of total B-cells between controls and IPF patients. Flow cytometric quantification of total B-cells (CD19+) in blood, lungs and lymph nodes (LN) as percentage of alive cells. For blood samples data also depicted as absolute number of B-cells per ml blood.
Heukels, Peter   +13 more
openaire   +1 more source

Supplemental_Material_Covalent_BTK_by_Harris,_et_al – Supplemental material for Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton’s Tyrosine Kinase

open access: yes, 2018
Supplemental material, Supplemental_Material_Covalent_BTK_by_Harris,_et_al for Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton’s Tyrosine Kinase by Christopher M. Harris, Sage E. Foley, Eric R.
Mark Michalak (5510279)   +5 more
core   +1 more source

sj-docx-1-msj-10.1177_13524585231192460 – Supplemental material for Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor

open access: yes, 2023
Supplemental material, sj-docx-1-msj-10.1177_13524585231192460 for Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor by Amit Bar-Or, Anne H Cross, Anthony
Elise E Drouin (16904347)   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy